Immunotherapy Shows Limited Benefit in Limited-Stage Little Cell Lung Cancer, Twice-Daily Radiation Linked to Improved Survival

A recent international clinical trial, NRG-LU005, has revealed that adding the immunotherapy drug atezolizumab to standard chemoradiation did not significantly improve survival rates for patients with limited-stage small cell lung cancer (LS-SCLC). Although, the study highlighted a notable benefit associated with twice-daily radiation therapy, suggesting it may improve treatment outcomes.

Study Design and Findings

The NRG Oncology/Alliance LU005 trial, published in the Journal of Clinical Oncology on January 13, 2026 [2], involved 544 patients from the United States and Japan, enrolled between May 2019 and December 2023. Participants, diagnosed with LS-SCLC, received one cycle of chemotherapy (platinum/etoposide) before being randomly assigned to either chemoradiation alone or chemoradiation plus atezolizumab. [3]

The primary endpoint of the study was overall survival (OS). Results indicated a median OS of 36.1 months for the chemoradiation-alone arm compared to 31.1 months for the chemoradiation plus atezolizumab arm (hazard ratio [HR], 1.03; 95% CI, 0.80 to 1.32). [3] Progression-free survival (PFS) was too similar between the groups, with medians of 11.4 months and 12.1 months, respectively (HR, 0.98; 95% CI, 0.79 to 1.22). [3] Distant-metastasis-free survival (DMFS) showed a median of 13.0 months for the CRT-alone arm and 16.8 months for the CRT + atezolizumab arm (HR, 0.96; 95% CI, 0.76 to 1.21). [3]

The Role of Radiation Fractionation

Although the addition of atezolizumab did not demonstrate a survival benefit, the study revealed a consistent trend towards improved survival with twice-daily radiation therapy. Patients receiving radiation once daily had a 51% higher risk of death compared to those receiving it twice daily in the chemoradiotherapy-alone arm. A similar trend was observed in the atezolizumab arm.

Dr. Helen J. Ross, co-leader of the study, emphasized that the findings support the continued use of 45 Gy twice daily as the preferred thoracic radiation regimen for patients with early-stage small cell lung cancer. [4] Despite decades of evidence supporting twice-daily radiation, its implementation remains low, potentially due to logistical challenges for patients and healthcare providers.

Implications for Future Research

The NRG-LU005 trial underscores the importance of optimizing radiation therapy schedules in the treatment of LS-SCLC. Researchers continue to investigate the role of immunotherapy in this disease, seeking to identify strategies that can enhance its effectiveness, particularly in earlier stages. [1]

“We continue to research the optimal use of immunotherapy in early-stage small cell lung cancer,” said Dr. Ross. [4]